Abstract:Anaplastic lymphoma kinase (ALK) is an orphan receptor tyrosine kinase (RTK), structurally belonging to the insulin receptor family. The identification of ALK fusion genes NPM-ALK and EML4-ALK in ALCL and NSCLC respectively, and clinical outcomes resulting from aberrant ALK signalling in different human cancers has confirmed the emergence of ALK as a novel and promising ‘personalized’ anticancer drug target. The development of small molecule ALK inhibitors has been accelerated and validated by the recent approval of crizotinib. Unfortunately, similar to other RTK inhibitors, resistance to crizotinib has been reported within a year of starting therapy. Different from the acquired resistance to EGFR inhibitors, the resistance to crizotinib was much more complex and driven by more than twenty secondary mutations, including the gate-keeper L1196M, and the C1156Y near the α-C-helix. In the course of our drug discovery program toward the discovery of novel ALK inhibitors, we took advantage of the 2,4-diarylaminopyrimidine (DAAP) scaffold that has long been recognized as a classical kinase inhibitor motif (TAE684) by introducing an amino acid side chain to the solvent interaction region to bring in additional H-bondings. Therefore, a series of new DAAP analogues (DAAPalogues) were developed and one compound SOMCL-12-81 was identified with high potency against both wild type ALK and L1196M mutations with IC50 values of 2.7 nM and 15.3 nM, respectively. In cellular assay, SOMCL-12-81 displayed an IC50 value of 3.0 nM against the proliferation of EML4-ALK dependent Karpass-299 cells. It was relatively selective (>10-fold) against a panel of in-house 20 RTKs. Dose-dependent tumor growth inhibition was observed in the BF3 rat xenograft model carrying the EML4-ALK fusion gene with daily administration of SOMCL-12-81. The high potency of SOMCL-12-81 both in vitro and in vivo allows it for further investigation. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B99. Citation Format: Zilan Song, Jing Ai, Zhiqing Liu, Xia Peng, Yi Chen, Jian Ding, Meiyu Geng, Ao Zhang. Discovery of 2,4-diarylaminopyrimidine SOMCL-12-81 as a potent inhibitor targeting both wild and mutant ALK kinases. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B99.

Novel 2,4-Diarylaminopyrimidine Analogues (daapalogues) Showing Potent C-Met/alk Multikinase Inhibitory Activities.

Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (daapalogues) Showing Potent Inhibitory Activities Against Both Wild-Type and Mutant Alk Kinases

Design, Synthesis and Pharmacological Evaluation of 2-(Thiazol-2-amino)-4-arylaminopyrimidines As Potent Anaplastic Lymphoma Kinase (ALK) Inhibitors

Synthesis and Anti-Tumor Efficacy of Novel 2, 4-Diarylaminopyrimidine Derivatives Bearing N-(3-pyridinylmethyl) Urea Moiety As Anaplastic Lymphoma Kinase Inhibitors.

Design, Synthesis and Biological Evaluation N2-(2-alkyoxy-6-aliphatic Aminopyridin-3-yl)-2,4-diaminepyrimidine Derivatives Bearing Acylamino or DBTD ‘head’ As Potential ALK Inhibitors

Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors

Abstract B99: Discovery of 2,4-Diarylaminopyrimidine SOMCL-12-81 As a Potent Inhibitor Targeting Both Wild and Mutant ALK Kinases.

Synthesis And Evaluation Of Novel 2,4-Diaminopyrimidines Bearing A Sulfoxide Moiety As Anaplastic Lymphoma Kinase (Alk) Inhibition Agents

Novel [1,2,4] Triazol [4,3-A] Pyridine Derivatives As Potential Selective C-Met Inhibitors with Improved Pharmacokinetic Properties

Identification and Anti-Tumor Evaluation of 3-Acyl-indol-based 2,4-Diarylaminopyrimidine Analogues As Potent ALK Inhibitors Capable of Overcoming Drug-Resistant Mutants.

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Dithiocarbamate Moiety As Novel FAK Inhibitors with Antitumor and Anti-Angiogenesis Activities.

Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Sulfonamide Moiety As Novel FAK Inhibitors

Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors

Selective Mechanisms and Molecular Design of 2,4 Diarylaminopyrimidines As ALK Inhibitors.

Discovery of 2-Aminopyridines Bearing a Pyridone Moiety As Potent ALK Inhibitors to Overcome the Crizotinib-Resistant Mutants

Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1

Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.

Dual Potent ALK and ROS1 Inhibitors Combating Drug-Resistant Mutants: Synthesis and Biological Evaluation of Aminopyridine-Containing Diarylaminopyrimidine Derivatives.

Pyridazinone Derivatives Displaying Highly Potent and Selective Inhibitory Activities Against C-Met Tyrosine Kinase.